| P2093 | author name string | Pankaj Sharma | |
| | Robert J Edwards | |
| | Peter McColgan | |
| | Paul Bentley | |
| | Nazeeha Hasan | |
| P2860 | cites work | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 |
| | Thrombolysis for acute ischaemic stroke | Q24247962 |
| | Estimating the mean and variance from the median, range, and the size of a sample | Q24801782 |
| | Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 |
| | Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey | Q28192728 |
| | FUNCTIONAL EVALUATION: THE BARTHEL INDEX | Q28201591 |
| | Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. | Q30878935 |
| | Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial | Q32137268 |
| | Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator | Q33823616 |
| | Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality | Q33959166 |
| | Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview | Q34093891 |
| | Interobserver agreement for the assessment of handicap in stroke patients. | Q34176187 |
| | The Canadian Neurological Scale: a preliminary study in acute stroke | Q34189037 |
| | Cerebral vascular accidents in patients over the age of 60. II. Prognosis | Q34241339 |
| | Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. | Q34263891 |
| | Distinguishing between stroke and mimic at the bedside: the brain attack study | Q34495419 |
| | Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke | Q34658675 |
| | Stroke rehabilitation: analysis of repeated Barthel index measures | Q34697117 |
| | Clinical biomarkers in drug discovery and development | Q35167912 |
| | Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke | Q36142617 |
| | Mechanisms of brain injury after intracerebral haemorrhage. | Q36345249 |
| | Reasons why few patients with acute stroke receive tissue plasminogen activator. | Q36472116 |
| | Inflammation after intracerebral hemorrhage | Q36620460 |
| | The inflammatory response in stroke | Q36692346 |
| | Challenges of cancer biomarker profiling | Q36962561 |
| | Biomarkers for cardiovascular disease: challenges and future directions | Q37166894 |
| | Stroke: the bare essentials | Q37223195 |
| | Blood biomarkers in the diagnosis of ischemic stroke: a systematic review | Q37227913 |
| | The challenge of acute-stroke management: does telemedicine offer a solution? | Q37244566 |
| | C-reactive protein and coronary heart disease: predictive test or therapeutic target? | Q37359826 |
| | Blood markers for the prognosis of ischemic stroke: a systematic review | Q37415033 |
| | Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options | Q37478454 |
| | Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment | Q37635613 |
| | Blood-brain barrier impairment with enhanced SP, NK-1R, GFAP and claudin-5 expressions in experimental cerebral toxocariasis | Q39178571 |
| | Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience | Q39530622 |
| | Decreased mortality by normalizing blood glucose after acute ischemic stroke | Q39743378 |
| | Plasma resistin levels and risk of myocardial infarction and ischemic stroke | Q40094952 |
| | Late secondary ischemic injury in patients receiving intraarterial thrombolysis | Q40620029 |
| | Shared mechanisms of ischaemic and haemorrhagic stroke: still a lot to learn | Q42765084 |
| | Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke | Q43276318 |
| | Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters | Q43599419 |
| | Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. | Q45096508 |
| | Homocysteine and stroke: evidence on a causal link from mendelian randomisation | Q45225758 |
| | Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. | Q45988489 |
| | Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. | Q46023236 |
| | Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses | Q46207178 |
| | Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study | Q46403811 |
| | Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. | Q46420379 |
| | Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. | Q46704364 |
| | Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator | Q46960607 |
| | Early Biomarkers of Stroke | Q48193653 |
| | Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke | Q48261685 |
| | New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. | Q48342084 |
| | Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke | Q48472263 |
| | Proton NMR analysis of plasma is a weak predictor of coronary artery disease | Q48547379 |
| | Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. | Q48741097 |
| | Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke | Q48822422 |
| | IL-6: an early marker for outcome in acute ischemic stroke | Q48899503 |
| | Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. | Q51464560 |
| | Reporting recommendations for tumor marker prognostic studies (remark). | Q53252865 |
| | Body iron stores and early neurologic deterioration in acute cerebral infarction | Q57236042 |
| | The Increase of Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke Is Associated With Good Outcome | Q60589474 |
| | Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis | Q61891118 |
| | The Canadian Neurological Scale: validation and reliability assessment | Q69591988 |
| | Measurements of acute cerebral infarction: a clinical examination scale | Q69660651 |
| | Progression of ischaemic stroke and excitotoxic aminoacids | Q71975978 |
| | Proinflammatory cytokines and early neurological worsening in ischemic stroke | Q73048866 |
| | Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients | Q80232641 |
| | Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project | Q81105578 |
| | High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA | Q81153111 |
| | Panel of biomarkers predicts stroke | Q81250605 |
| | Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke | Q82737605 |
| | Translational medicine for stroke drug discovery: the pharmaceutical industry perspective | Q82876207 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | systematic review | Q1504425 |
| P304 | page(s) | 230-240 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review | |
| P478 | volume | 74 | |